Posted AT 5:05 PM EDT on 16/05/08
Biovail, U.S. settle over Cardizem
Biovail Corp. on Friday settled another of the many legal and regulatory battles that began when founder Eugene Melnyk was running the drug maker, and urged shareholders to put Mr. Melnyk's era behind it.
The company said its subsidiary Biovail Pharmaceuticals Inc. will pay $24.6-million (U.S.) to the U.S. Department of Justice to settle allegations related to the launch of its Cardizem heart drug.
The full text of this article has 598 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
